Advertisement

Picture EBD Group BIO-Europe 2021 Digital BEU2021 650x80

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in Europe and Israel or involving organisations from these countries.

Total search results: 6676 | Ordered by Deal: Collaboration or Financing (descending)
1 2 3 ... 65 66 67  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Zukunftsfonds Heilbronn–Ampersand: investment, 202107 acquisition of majority share in PPS from ZFHN and merger with portfolio company GeneWerk 2021-07-01
Ziylo–Novo Group: investment, 201808 acquisition 100% for up to $800m in upfront + milestone payments by Novo Nordisk 2018-08-17
Ziphius Vaccines–SEVERAL: investment, 202105 financing round Series A €24.3m incl Belgian Family Offices 2021-05-25
Ziphius Vaccines–PERSON: investment, 202105 financing round Series A totalling €24.3m incl cornerstone investor Annie Vereecken 2021-05-25
Ziphius Vaccines–OTHER: credit, 202105 convertible loan €5m 2021-05-25
Ziarco–Novartis: investment, 201612 acquisition €na by Novartis ANNOUNCED 2016-12-16
Zelluna–SEVERAL: investment, 202006 equity financing tog with public grants totalling €7.5m 2020-06-11
Zelluna–SEVERAL: grant, 202006 public grants + equity financing tog totalling €7.5m 2020-06-11
Zelluna–Image Box: public relations, 201810 supply service existent by Image Box PR 2018-10-24
Zelluna–Glycostem Therapeutics: cell therapy contract manufacturing, 201911– collab developm + supply of TCR-guided NK-cell therapies 2019-11-19
Zellkraftwerk–Canopy Biosciences: investment, 201904 acquisition of Zellkraftwerk GmbH by Canopy Biosciences 2019-04-29
Zeincro–Excelya: investment, 202007 acquisition 2020-06-07
Zedira–Germany (govt): grant, 201611– BMBF KMU-Innovativ funding €1.5m for 3y to support developm of ZED1227 in diabetic nephropathy 2016-11-30
Zebra Medical Vision–SEVERAL: investment, 201504 seed financing round $8m led by Khosla Ventures 2015-04-06
Zebra Medical Vision–Khosla Ventures: investment, 201504 seed financing round totalling incl $8m lead investor Khosla Ventures 2015-04-06
Zebra Medical Vision–Blonde 2.0: public relations, 201710 service existent by Blonde 2.0 2017-10-27
Zealand Pharma–SEVERAL: investment, 201707–201708 US IPO of ADSs DKK566.4m at DKK112.58/share at Nasdaq Global Select Market 2017-07-06
Zavante Therapeutics–SEVERAL: investment, 201510 seed financing round 2015-10-09
Zavante Therapeutics–Nabriva: investment, 201807 acquisition upfront 8.2m Nabriva ordinary shares (=19.9% shareholding) + $97.5m milestones 2018-07-24
Zastra Innovations–Optibrium: drug discovery software, 201701– distribution excl of StarDrop s/w in India by Zastra Innovations 2017-01-31
Z Factor–SEVERAL: investment, 201705 financing round Series A £7m led by exising investor Medicxi 2017-05-03
Yumda–Chemie.DE: investment, 201704 acquisition of Yumda GmbH by Chemie.DE Information Service GmbH 2017-04-01
Yukin Therapeutics–SEVERAL: investment, 201906 financing round €3.3m co-led by Advent France Biotechnology + Medicxi 2019-06-04
Yukin Therapeutics–NewCap: public relations, 201906 service existent by NewCap 2019-06-04
Yukin Therapeutics–Medicxi Ventures: investment, 201906 financing round totalling €3.3m incl new + co-lead investor Medicxi 2019-06-04
Yukin Therapeutics–Advent France Biotechnology: investment, 201906 financing round totalling €3.3m incl founding + co-lead investor Advent France Bio 2019-06-04
Ysios Capital–SEVERAL: investment, 202006 first closing €155m of Ysios BioFund III with target size of €200m 2020-06-10
Yposkesi–Andrew Lloyd Associates: public relations, 201807 service existent by ALA 2018-07-09
Yourgene Bioscience–Premaitha: investment, 201612–201702 acquisition of Yourgene Bioscience Co Ltd by Premaitha Health plc 2016-12-21
Young In Group–Eurofins: investment, 201804 acquisition of Lab Frontier Co Ltd from YIG by Eurofins 2018-04-03
Ynsect–SEVERAL: investment, 202010 financing round Series C extension to total of $372m led by Astanor Ventures 2020-10-06
Ynsect–SEVERAL: investment, 201902 financing round Series C €110m ($125m) led by Astanor Ventures 2019-02-21
Yingsheng Biotechnology–Biotage: clinical mass spectrometry, 201906– collab strategic + OEM sale in China by Shandong Yingsheng Biotechnology 2019-06-04
Yahong Meditech–Photocure: Cevira®, 201907– license ww developm + commercialisation to Asieris up to $250m milestones + royalties 2019-07-01
XtalPi–Swiss Investment Group: investment, 202009 financing round Series C totalling $318.8m incl existing + co-investor SIG 2020-09-28
XtalPi–SEVERAL: investment, 202009 financing round Series C $318.8m co-led by SoftBank Vision Fund 2 + PICC Capital + Morningside 2020-09-28
Xpand Biotechnology–Kuros: investment, 201612 merger acquisition of Xpand Biotechnology BV by Kuros Biosciences AG for up to 2.105m new Kuros shares 2016-12-19
Xigen–Instinctif Partners: public relations, 201701 service existent by Instinctif Partners 2017-01-05
Xenothera–SEVERAL: investment, 202106 financing round €20m led by new investor EIC Fund with €10m 2021-06-29
Xenothera–EU (govt): investment, 202106 financing round totalling €20m incl €10m from new + lead investor EIC Fund 2021-06-29
XenoGesis–Sygnature Discovery: investment, 202009 acquisition of XenoGesis by Sygnature Discovery 2020-09-24
Xenikos–SEVERAL: investment, 201805 financing round Series B $30m incl new investors Medicxi Ventures + RA Capital Management 2018-05-15
Xencor–Selexis: cell line development, 201611– supply service strategic agreem for SUREtechnology for developm of multi-specific antibodies 2016-11-03
Xencor–Selexis: cell line development, 2011– supply service agreem for SUREtechnology for developm of multi-specific antibodies 2011-01-01
Xencor–JSR Corp: cell line development, 201802– four commercial licenses to use Selexis’ SUREtechnology for developm of bispecific antibodies 2018-02-26
Xencor–Canale Communications: public relations, 201803 service existent by Canale 2018-03-20
Xeltis–SEVERAL: investment, 201711 financing round Series C €45m led by a global strategic investor + incl Ysios Capital + LSP + Kurma Partners et al 2017-11-15
Xell AG–Sartorius: investment, 202107 acquisition €50m plus two revenue-based earn-out components in 2022 to 2025 2021-07-29
Xconomy–Informa: investment, 201608 acquisition 100% £1m upfront + £1.5m milestones+deferred of Xconomy Inc by Informa 2016-08-31
X4 Pharmaceuticals–Arsanis: investment, 201811– reverse merger with former X4 owners to hold 70% + Arsanis to be renamed X4 ANNOUNCED 2018-11-27
WuXi PharmaTech–Ally Bridge Group: investment, 201702 existent investment of ABG 2017-02-23
Wren Therapeutics–SEVERAL: investment, 201901 financing round Series A £18m from Baupost Group + LifeForce Capital + high net worth individuals 2019-01-22
Wren Therapeutics–LifeForce Capital: investment, 201901 financing round Series A totalling £18m including co-investor LifeForce Capital 2019-01-22
Wren Therapeutics–Baupost Group: investment, 201901 financing round Series A totalling £18m including lead investor The Baupost Group 2019-01-22
Wondfo Biotech–Biocartis: molecular diagnostics, 201809– collab 50/50 joint venture for commercialisation of Idylla platform in mainland China 2018-09-03
Wise (IT)–SEVERAL: investment, 202010 financing round Series C €15m led by CDP Venture Capital SGR 2020-10-01
Wise (IT)–SEVERAL: investment, 201705 financing round Series B €6.5m led by Principia SGR + incl Atlante Ventures + HTGF + F3F + Antares 2017-05-25
Wilson Therapeutics–Alexion: investment, 201804–201805 cash tender offer SEK7.1b ($855m) with SEK232/share by Alexion 2018-04-11
Wiley–Bio-Rad: spectral libraries, 201612 collab product integration launch of Wiley Spectral Lab powered by Bio-Rad’s KnowItAll 2016-07-26
Wilex–SEVERAL: investment, 201704– capital increase €4.99m with rights issue to existing shareholders incl dievini Hopp 2017-04-24
Wilex–Hopp Group: investment, 201702– financing commitment of up to €10m by Dievini Hopp [not announced whether credit or investment] 2017-02-06
Westwicke Partners–ICR: investment, 201901 acquisition of Westwicke by ICR 2019-01-03
Werfen–Protagen: biomarker, 201608– license semi-excl for use of BICD2 biomarker for diagnosis of systemic sclerosis to Inova Diagnostics 2016-08-11
Wellington Partners–UTIMCO: investment, 201907 final closing totalling €210m WPLS-V fund incl new investor UTIMCO 2019-07-31
Wellington Partners–Univ Texas: investment, 201907 final closing totalling €210m WPLS-V fund incl new investor Univ Texas/Texas A&M Investment Company 2019-07-31
Wellington Partners–Talanx: investment, 201907 final closing totalling €210m WPLS-V fund incl new investor Talanx 2019-07-31
Wellington Partners–SEVERAL: investment, 201907 final closing €210m WPLS-V fund incl investors KfW Capital + Talanx + UTIMCO + Univ Texas + EIB 2019-07-31
Wellington Partners–MC Services: public relations, 202001 service existent by MC Services 2020-01-08
Wellington Partners–Germany (govt): investment, 201907 final closing totalling €210m WPLS-V fund incl new investor KfW Capital 2019-07-31
Wellington Partners–EU (govt): investment, 201907 final closing totalling €210m WPLS-V fund incl exisiting investor EIB/EIF 2019-07-31
Wellington Partners–Consilium: public relations, 201907 service existent by CSC 2019-07-31
Wellington Partners–CMS: legal services, 201811 supply service legal advice by CMS for both lead investors HBM + Wellington of Adrenomed Series D 2018-11-01
Welch Materials–DataApex: chromatography s/w, 201803– distribution Hangzhou Welch Scientific Instruments to market OEM version of Clarity in China 2018-03-15
Weizmann Institute–Bruker: MRI system, 201710 supply Biospec 15.2 Tesla USR preclinical UHF MRI system 2017-10-18
Waters–Spectris: analytical instruments, 201801– collab co-marketing agreem with Malvern Panalytical for Omnisec Reveal with Acquity APC system 2018-01-16
Waters–Omic Analytics: mass spectrometry software, 201703– license excl for sale of Proteolabels s/w with Progenesis QI for Proteomics 2017-03-15
Waters–Molecular Discovery: mass spectrometry s/w, 201808– collab product integration MetaSite + MassMetaSite s/w with UNIFI Platform 2018-08-02
Waters–Heidrick & Struggles: recruitment services, 202007 supply service placement of Udit Batra as CEO of Waters 2020-07-01
Waters–Andrew Alliance: automated liquid handling technology, 201902–collab new solutions for LC-MS research 2019-02-06
Waters–Andrew Alliance: automated liquid handling technology, 201706– collab co-marketing semi-automated sample prep solution 2017-06-01
Warp Drive Bio–Revolution Medicines: investment, 201810 acquisition of Warp Drive Bio by Revolution Medicines 2018-10-16
VTU–KonValue: investment, 201810 acquisition of VTU Technology by KonValue Group from VTU Holding GmbH + renaming as Validogen GmbH 2018-10-22
Voluntis–SEVERAL: investment, 202011 capital increase €5.93m net €5.7m led by Debiopharm Innovation Fund 2020-11-23
Voluntis–SEVERAL: investment, 201805 IPO €30.1m at Euronext Paris with 2.15m new shares at €14/share 2018-05-30
Voluntis–Salesforce: CRM software, 201912– collab using Salsesforce cloud + analytics s/w to implement VPS DTx prescription + reimbursement 2019-12-16
Voluntis–Indigo (Eric Carreel): investment, 202011 capital increase totalling €5.93m incl €1m from existing + co-investor Indigo 2020-11-23
Voluntis–Debiopharm: investment, 202011 capital increase totalling €5.93m incl €3.92m from new + lead investor Debiopharm Innovation Fund 2020-11-23
Voluntis–Aptar: investment, 202106– cash tender offer €78.8m at €8.7/share announced with 64.6% committed by reference shareholders 2021-07-23
Volta Medical–SEVERAL: investment, 202101 financing round $28m led by Gilde Healthcare 2021-01-05
Volta Medical–Gilde Investment: investment, 202101 financing round totalling $28m incl lead investor Gilde Healthcare 2021-01-05
Volastra Therapeutics–Droia Ventures: investment, 202105 existent portfolio company of Droia 2021-05-17
Vivoryon–Trophic Communications: public relations, 201910 service existent by Trophic 2019-10-08
Vivoryon–SEVERAL: investment, 201910– public rights offering €30m–€70m incl Claus Chrisitansen + Den Danske Forskningsfond + T&W Holding + MorphoSys 2019-10-08
Vivoryon–MorphoSys: investment, 201910– public rights offering totalling €30m–€70m incl €15m but limited to max 19.98% holding from MorphoSys AG 2019-10-08
Vivoryon–MC Services: public relations, 201910 service existent by MC Services 2019-10-08
Vividion Therapeutics–SEVERAL: investment, 202102 financing round Series C $135m co-led by new investors Logos Capital + Boxer Capital 2021-02-24
Vividion Therapeutics–SEVERAL: investment, 201904 financing round Series B $82m led by new investor Nextech Invest 2019-04-30
Vividion Therapeutics–Nextech: investment, 201904 financing round Series B totalling $82m incl new + lead investor Nextech Invest 2019-04-30
Vividion Therapeutics–Casdin Capital: investment, 201904 financing round Series B totalling $82m incl new + co-investor Casdin Capital 2019-04-30
Vividion Therapeutics–Bayer: investment, 202108– acquisition $1.5b upfront + $500k milestones ANNOUNCED 2021-08-05
1 2 3 ... 65 66 67  next pagenext page



Advertisement

Picture [iito] Made Without Love 650x80px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Advertisement

Picture Demy-Colton BioFuture 2021 NYC D Meet Top Investors 650x300px

» top